Hypogonadism is a known late effect of cancer treatment. Hypogonadism requires replacement of sex steroids to ensure appropriate development of secondary sex characteristics, growth, and other beneficial health effects. We present a cancer survivor with hypogonadotropic hypogonadism and gender dysphoria. The patient received gender affirming care in our gender clinic with a multidisciplinary team that included an endocrinologist. This is not an isolated case at our institution. Survivorship oncologists must include a discussion about gender concurrently with conversations about survivors' development of puberty. Conversations should start early to ensure appropriate referrals and gender affirming hormone replacement.
Get full access to this article
View all access options for this article.
References
1.
HewittM, WeinerSL, SimoneJV. (Eds). NRC. Childhood cancer survivorship: improving care and quality of life. Washington, DC: National Academies Press;. 2003.
2.
National Cancer Institute. Adolescent and young adults (AYA) cancers quiz. Accessed June2, 2015 from: www.cancer.gov/types/aya/quiz
3.
MillerKD, NogueiraL, MariottoAB, et al.Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; Epub ahead of print]; DOI: 10.3322/caac.21565.
4.
Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 5.0. Accessed April14, 2019 from: www.survivorshipguidelines.org
5.
RoseSR, HorneVE, HowellJ, et al.Late endocrine effects of childhood cancer. Nat Rev Endocrinol. 2016; 12(6):319–36.
6.
ChemaitillyW, LiZ, HuangS, et al.Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St. Jude Lifetime Cohort Study. J Clin Oncol. 2015; 33(5):492–500.
7.
RosenfieldRL, CookeDW, RadovickS.Puberty and its disorders in the female. In: SperlingMA (Ed). Pediatric endocrinology, 4th edition. Philadelphia, PA: Elsevier Saunders; 2014; pp. 615–27.
8.
PalmertMR, DunkelL, Feldman WitchelS.Puberty and its disorders in the male. In: SperlingMA (Ed). Pediatric endocrinology, 4th edition. Philadelphia, PA: Elsevier Saunders; 2014; pp. 724–25.
9.
ColemanE, BocktingW, BotzerM, et al.Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend. 2012; 13:165–232.
10.
SalehiP, DivallSA, CrouchJM, et al.Review of current care models for transgender youth and application to the development of a multidisciplinary clinic-the Seattle Children's Hospital experience. Pediatr Endocrinol Rev. 2018; 15:280–90.
11.
de VriesAL, McGuireJK, SteensmaTD, et al.Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics. 2014; 134:696–704.
12.
GridleySJ, CrouchJM, EvansY, et al.Youth and caregiver perspectives on barriers to gender-affirming health care for transgender youth. J Adolesc Health. 2016; 59:254–61.
13.
HembreeWC, Cohen-KettenisPT, GoorenL, et al.Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017; 102(11):3869–903.
14.
RaffertyJ.Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics. 2018; 142(4):e20182162.
15.
SchabathMB, BlackburnCA, SutterME, et al.National Survey of Oncologists at National Cancer Institute-designated comprehensive cancer centers: attitudes, knowledge, and practice behaviors about LGBTQ patients with cancer. J Clin Oncol. 2019; 37(7):547–58.
16.
GurneyJG, KrullKR, Kadan-LottickN, et al.Social outcomes in the childhood cancer survivor study cohort. J Clin Oncol. 2009; 27(14):2390–5.
17.
KenneyLB, CohenLE, ShnorhavorianM, et al.Male reproductive health after childhood, adolescent, and young adult cancers: a report from the children's oncology group. J Clin Oncol. 2012; 30(27):3408–16.
18.
MetzgerML, MeachamLR, PattersonB, et al.Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol. 2013; 31(9):1239–47.
